Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb
24 July 2023 - 9:00PM
Tuebingen,
Germany and
Houston,
TX,
July 24,
2023 – Immatics N.V. (NASDAQ: IMTX,
“Immatics”), a clinical-stage biopharmaceutical company active in
the discovery and development of T cell-redirecting cancer
immunotherapies, today announced that Bristol Myers Squibb (NYSE:
BMY) has made a $35 million equity investment in Immatics. Bristol
Myers Squibb purchased 2,419,818 ordinary shares in a private
placement transaction at a subscription price per share of $14.461.
Additionally, Bristol Myers Squibb has the right to appoint a
member to the Immatics Scientific Advisory Board.
“This investment is further testimony to the
strength of the relationship and of our differentiated platform
technologies that are the foundation of our TCR-based cell
therapies and bispecifics,” commented Harpreet Singh, Ph.D., CEO
and Co-Founder of Immatics. “We remain steadfast in our commitment
to advancing innovative treatment options for patients in their
fight against cancer, and look forward to providing further
clinical results in the second half of the year.”
The securities referenced above have not been
registered under the Securities Act of 1933, as amended, or any
state or other applicable jurisdiction’s securities laws, and may
not be offered or sold in the United States absent registration or
an applicable exemption from the registration requirements of the
Securities Act and applicable state or other jurisdictions’
securities laws.
– END –
About ImmaticsImmatics combines
the discovery of true targets for cancer immunotherapies with the
development of the right T cell receptors with the goal of enabling
a robust and specific T cell response against these targets. This
deep know-how is the foundation for our pipeline of Adoptive Cell
Therapies and TCR Bispecifics as well as our partnerships with
global leaders in the pharmaceutical industry. We are committed to
delivering the power of T cells and to unlocking new avenues for
patients in their fight against cancer.
Immatics intends to use its website
www.immatics.com as a means of disclosing material non-public
information. For regular updates you can also follow us on Twitter,
Instagram and LinkedIn.
Forward-Looking
Statements:Certain statements in this press release may be
considered forward-looking statements. Forward-looking statements
generally relate to future events or Immatics’ future financial or
operating performance. For example, statements concerning the
timing of product candidates and Immatics’ focus on partnerships to
advance its strategy are forward-looking statements. In some cases,
you can identify forward-looking statements by terminology such as
“may”, “should”, “expect”, “intend”, “will”, “estimate”,
“anticipate”, “believe”, “predict”, “potential” or “continue”, or
the negatives of these terms or variations of them or similar
terminology. Such forward-looking statements are subject to risks,
uncertainties, and other factors which could cause actual results
to differ materially from those expressed or implied by such
forward-looking statements. These forward-looking statements are
based upon estimates and assumptions that, while considered
reasonable by Immatics and its management, are inherently
uncertain. New risks and uncertainties may emerge from time to
time, and it is not possible to predict all risks and
uncertainties. Factors that may cause actual results to differ
materially from current expectations include, but are not limited
to, various factors beyond management's control including general
economic conditions and other risks, uncertainties and factors set
forth in filings with the SEC. Nothing in this press release should
be regarded as a representation by any person that the
forward-looking statements set forth herein will be achieved or
that any of the contemplated results of such forward-looking
statements will be achieved. You should not place undue reliance on
forward-looking statements, which speak only as of the date they
are made. Immatics undertakes no duty to update these
forward-looking statements.
For more information, please contact:
Media and Investor Relations Contact |
Eva Mulder or Charlotte Spitz |
|
Trophic Communications |
|
Phone: +31 6 52 33 15 79 |
|
immatics@trophic.eu |
|
Immatics N.V. |
|
Anja Heuer |
Jordan Silverstein |
Senior Director, Corporate Communications |
Head of Strategy |
Phone: +49 89 540415-606 |
Phone: +1 281 810 7545 |
media@immatics.com |
InvestorRelations@immatics.com |
1 Exact price per share $14.4639
- 20230724_Immatics_BMS Equity Investment_EN_final
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From Sep 2023 to Sep 2024